Awards recognize exceptional progress in bringing technological advancements to healthcare
Cambridge, UK, December 6, 2016: Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced today that its ReCIVA breath sampling and analysis technology has been named Invention of the Year in the 2017 Top 50 in Digital Health Awards.
Each year ahead of the JP Morgan Health Conference in San Francisco, fifty of the leading entrepreneurs, investors, technologists, reporters, and providers dedicated to bringing technological advancements to healthcare are recognized at the Top 50 in Digital Health Dinner hosted by Rock Health, Fenwick & West, Goldman Sachs, and Square 1 Bank. Within the Top 50, a number of individuals and organizations are awarded through public nominations and votes from the digital health community for making exceptional progress in driving resources, attention, and innovation toward a massively better healthcare system.
Owlstone Medical uses the Respiration Collector for In Vitro Analysis (ReCIVA), in combination with the Field Asymmetric Ion Mobility Spectrometer ( FAIMS) sensor platform, to accurately and selectively detect targeted biomarkers of disease in breath (and other bodily fluids).
Billy Boyle, co-founder and CEO at Owlstone Medical, said:
We are delighted that ReCIVA has been named Invention of the Year in the 2017 Top 50 Digital Health Awards. Our vision is to save 100,000 lives and $1.5B in health care costs by 2020 with a breath sampling and analysis technology that can diagnose cancer and other diseases earlier than existing tests. This allows for more effective treatment and ultimately, better patient survival rates and reduced treatment costs.
Notes to Editors
Owlstone Medical’s ReCIVA Breath Sampler
For a high resolution image please contact firstname.lastname@example.org
For more information please contact:
Sarah Jeffery, Zyme Communications
+44 (0)7771 730 919
About Owlstone Medical
Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in health care costs by 2020.
The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids). FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.
Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications.
Founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge, Owlstone Inc is a profitable business selling its proven FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialise FAIMS in diagnostic applications.
Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK.